PMID- 27771776
OWN - NLM
STAT- MEDLINE
DCOM- 20170523
LR  - 20181202
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 22
IP  - 2
DP  - 2017 Apr
TI  - Multidisciplinary evaluation at baseline and during treatment improves the rate 
      of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
PG  - 380-386
LID - 10.1007/s10147-016-1042-5 [doi]
AB  - BACKGROUND: Deferasirox (DFX) is used to reduce iron levels in patients with 
      myelodysplastic syndrome (MDS) who develop iron overload after chronic red blood 
      cell infusions. However, DFX can be associated with renal and gastrointestinal 
      toxicities, which may cause treatment interruption or discontinuation. This study 
      aimed to determine the effectiveness and safety of DFX in patients with MDS. 
      METHODS: This multicenter, retrospective, observational study was conducted at 
      two hospitals in Italy. Elderly patients with transfusion-dependent MDS received 
      DFX for up to 12 months and were divided into two groups: group A comprised 
      patients who were not under multidisciplinary assessment; group B comprised 
      patients under multidisciplinary control. Treatment effectiveness was estimated 
      by monitoring the serum ferritin (SF) levels throughout the study. Any 
      treatment-related adverse events (AEs), clinically relevant analytical 
      alterations, and reasons for treatment discontinuation were monitored. RESULTS: 
      The study included 44 patients (13 female, 31 male; median age 77.0 years). At 
      3 months, SF levels decreased by >/=20 % in 29 and 31 % of patients in groups A and 
      B, respectively, in 17 and 36 % of patients at 6 months, and in 22 and 58 % at 
      12 months. The most common AEs were diarrhea and increased serum creatinine, 
      which were more frequent in group A. The discontinuation rate after renal AE was 
      15 and 5 % in groups A and B, respectively. CONCLUSION: Multidisciplinary 
      evaluation can be an effective strategy for monitoring renal function in patients 
      on DFX therapy, to improve treatment adherence and overall efficacy in elderly 
      patients with MDS.
FAU - Del Corso, Lisette
AU  - Del Corso L
AD  - Internal Medicine, Department of Hematology and Oncology, IRCCS AOU San 
      Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy.
FAU - Biale, Lucia
AU  - Biale L
AD  - Blood Bank, Department of Health Management, AOU City Health Presidium Molinette, 
      Corso Bramante 88, 10126, Turin, Italy.
FAU - Parodi, Emanuele Luigi
AU  - Parodi EL
AD  - Nephrology, Department of Internal Medicine and Medical Specialties, IRCCS AOU 
      San Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy.
FAU - Russo, Rodolfo
AU  - Russo R
AD  - Nephrology, Department of Internal Medicine and Medical Specialties, IRCCS AOU 
      San Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy.
FAU - Filiberti, Rosa
AU  - Filiberti R
AD  - Clinical Epidemiology, IRCCS AOU San Martino-IST, Largo R. Benzi, 10, 16132, 
      Genoa, Italy.
FAU - Arboscello, Eleonora
AU  - Arboscello E
AD  - Internal Medicine, Department of Hematology and Oncology, IRCCS AOU San 
      Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy. 
      eleonora.arboscello@alice.it.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20161022
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Benzoates)
RN  - 0 (Iron Chelating Agents)
RN  - 0 (Triazoles)
RN  - V8G4MOF2V9 (Deferasirox)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Benzoates/*therapeutic use
MH  - Deferasirox
MH  - Female
MH  - Humans
MH  - Iron Chelating Agents/*therapeutic use
MH  - Iron Overload/*drug therapy/etiology
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*therapy
MH  - Retrospective Studies
MH  - *Transfusion Reaction
MH  - Treatment Outcome
MH  - Triazoles/*therapeutic use
OTO - NOTNLM
OT  - Compliance
OT  - Deferasirox
OT  - Efficacy
OT  - Elderly
OT  - Myelodysplastic syndrome
EDAT- 2016/10/25 06:00
MHDA- 2017/05/24 06:00
CRDT- 2016/10/25 06:00
PHST- 2016/06/28 00:00 [received]
PHST- 2016/09/12 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/05/24 06:00 [medline]
PHST- 2016/10/25 06:00 [entrez]
AID - 10.1007/s10147-016-1042-5 [pii]
AID - 10.1007/s10147-016-1042-5 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2017 Apr;22(2):380-386. doi: 10.1007/s10147-016-1042-5. Epub 
      2016 Oct 22.